Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

Aeterna Zentaris Inc. (NASDAQ: AEZS ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be